International: +1-347-960-6455
Trypanosomiasis Therapeutics - Pipeline Analysis 2018

Trypanosomiasis Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10075 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Infectious
Select License Type

Trypanosomiasis is an infectious disease caused by the parasite of the genus Trypanosoma. African trypanosomiasis, or sleeping sickness, is caused by Trypanosoma brucei parasites in sub-Saharan Africa and American trypanosomiasis, or Chagas disease, is caused by Trypanosoma cruzi parasites in Latin America and is transmitted by the triatomine or ‘kissing’ bug. The signs and symptoms observed in patients with trypanosomiasis are swollen lymph glands, blood in urine, fever, aching muscles and joints. Tsetse fly is the main vector for Trypanosoma. People in sub-Saharan African countries are mostly exposed to tsetse fly. Some of the complications associated with trypanosomiasis are wasting syndrome, aspiration pneumonia, anemia, meningoencephalitis, and seizures. Sequella Inc. is in the process of developing SQ109 as a cell wall inhibitor for the treatment of trypanosomiasis.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.